Effect of Telmisartan on Ambulatory Blood Pressure Monitoring, Plasma Brain Natriuretic Peptide, and Oxidative Status of Serum Albumin in Hemodialysis Patients

被引:0
作者
Hidetaka Shimada
Kenichiro Kitamura
Makoto Anraku
Taku Miyoshi
Masataka Adachi
Do Gia Tuyen
Shiho Wakamatsu
Hiroshi Nonoguchi
Motoko Tanaka
Kimio Tomita
机构
[1] Faculty of Medical and Pharmaceutical Sciences,Department of Nephrology
[2] Kumamoto University,Department of Nephrology
[3] Shimada Hospital,Department of Biopharmaceutics
[4] Faculty of Medical and Pharmaceutical Sciences,Department of Nephrology
[5] Kumamoto University,undefined
[6] Akebono Clinic,undefined
来源
Hypertension Research | 2005年 / 28卷
关键词
telmisartan; blood pressure; brain natriuretic peptide; oxidative stress; hemodialysis;
D O I
暂无
中图分类号
学科分类号
摘要
The effect of telmisartan on ambulatory blood pressure, plasma neurohormonal parameters, and oxidation of serum albumin has not been investigated in hemodialysis (HD) patients. Thirteen hypertensive HD patients were treated with 40 mg telmisartan once daily, and 24-h ambulatory blood pressure monitoring was performed after 0, 4, and 8 weeks of treatment. Plasma renin activity, plasma aldosterone concentration (PAC), brain natriuretic peptide (BNP) level, and serum oxidized albumin level were determined at the same time points. Serum telmisartan concentration was also measured at 4 and 8 weeks. Telmisartan significantly reduced systolic blood pressure and diastolic blood pressure (both awake and sleeping) after 4 weeks, and these pressures showed a further significant decrease after 8 weeks. Plasma levels of aldosterone, BNP, and serum oxidized albumin were markedly decreased after 4 weeks and these lower levels were maintained at 8 weeks. The trough serum telmisartan concentration was not significantly different at 8 weeks compared with 4 weeks. Throughout the treatment period, there were no significant adverse effects. Telmisartan effectively lowers blood pressure and reduces PAC, BNP, and oxidative stress and is safe and well-tolerated by HD patients. A long-term study in a large population is required to determine the influence of telmisartan therapy on cardiovascular mortality and morbidity in HD patients.
引用
收藏
页码:987 / 994
页数:7
相关论文
共 209 条
[1]  
Locatelli F(2000)Cardiovascular disease in chronic renal failure: the challenge continues Nephrol Dial Transplant 15 S69-S80
[2]  
Marcelli D(2000)The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world N Engl J Med 342 1-8
[3]  
Conte F(1994)Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells Circ Res 74 1141-1148
[4]  
van den Hoogen PCW(2000)Angiotensin II activates nuclear transcription factor κB through AT1 and AT2 in vascular smooth muscle cells: molecular mechanisms Circ Res 86 1266-1272
[5]  
Feskens EJM(1996)Direct Hypertension 27 32-35
[6]  
Nagelkerke NJD(2001) measurement of nitric oxide in mesenteric resistance arteries: increased decomposition by superoxide in hypertension Circulation 103 448-454
[7]  
Menotti A(2003)Angiotensin II-induced hypertension accelerates the development of atherosclerosis in ApoE-deficient mice J Am Coll Cardiol 42 905-910
[8]  
Nissinen A(2002)Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients Nephron 90 256-261
[9]  
Kromhout D(2001)Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease Ren Fail 23 685-692
[10]  
Griendling KK(2003)The effect of losartan on insulin resistance and beta cell function in chronic hemodialysis patients Cardiology 99 169-170